Gestalt's core product, PathFlow, is a digital pathology platform that integrates with laboratory information systems to enable remote case viewing, collaboration, and AI-powered image analysis. Customers include healthcare providers, academic medical centers, and research organizations that use the platform for faster, more accurate diagnoses and expert consultation. PathFlow supports biomarker scoring, image and data analysis for disease-progression studies, and interoperable workflows that reduce missed diagnoses and streamline pathologists' work. The company plans to use new funding to expand its customer base, enhance AI capabilities, and pursue FDA clearance. Management says the funding will also facilitate broader market adoption and increased profitability as the company scales. Founded in 2017 and based in Spokane, Gestalt positions its technology as a scalable, digital-first solution to address rising cancer rates and a declining number of practicing pathologists.

Total raised

$8M

Funding rounds

1

Latest round

Series A

Latest activity

Apr 2025